WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 596196
Description: JB-11 isethionate is a bioactive chemical.
MedKoo Cat#: 596196
Name: JB-11 isethionate
Chemical Formula: C21H29N5O7S
Molecular Weight: 495.55
Elemental Analysis: C, 50.90; H, 5.90; N, 14.13; O, 22.60; S, 6.47
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: JB-11 isethionate; NSC 328564; NSC-328564; NSC328564;
IUPAC/Chemical Name: 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)quinazoline-2,4-diamine 2-hydroxyethane-1-sulfonate
InChi Key: YATKEMOVGUXIDY-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H23N5O3.C2H6O4S/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3;3-1-2-7(4,5)6/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24);3H,1-2H2,(H,4,5,6)
SMILES Code: OCCS(=O)(O)=O.NC1=NC(N)=C2C(C)=C(CNC3=CC(OC)=C(OC)C(OC)=C3)C=CC2=N1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 495.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Smith D, Gazzard B. Treatment and prophylaxis of Pneumocystis carinii pneumonia in AIDS patients. Drugs. 1991 Oct;42(4):628-39. Review. PubMed PMID: 1723365.
2: Hughes WT. Prevention and treatment of Pneumocystis carinii pneumonia. Annu Rev Med. 1991;42:287-95. Review. PubMed PMID: 2035974.
3: Wordell CJ, Hauptman SP. Treatment of Pneumocystis carinii pneumonia in patients with AIDS. Clin Pharm. 1988 Jul;7(7):514-27. PubMed PMID: 3138063.
4: Masur H, Kovacs JA. Treatment and prophylaxis of Pneumocystis carinii pneumonia. Infect Dis Clin North Am. 1988 Jun;2(2):419-28. Review. PubMed PMID: 3060526.
5: Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, Masur H. Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired immunodeficiency syndrome (AIDS). Semin Oncol. 1988 Apr;15(2 Suppl 2):46-9. PubMed PMID: 2966985.
6: Hughes WT. Treatment and prophylaxis for Pneumocystis carinii pneumonia. Parasitol Today. 1987 Nov;3(11):332-5. PubMed PMID: 15462879.
7: Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, Simmons JT, Lack EE, Shelhamer JH, Balis F, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987 Oct 15;317(16):978-85. PubMed PMID: 2958710.
8: Queener SF, Bartlett MS, Jay MA, Durkin MM, Smith JW. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. Antimicrob Agents Chemother. 1987 Sep;31(9):1323-7. PubMed PMID: 2445281; PubMed Central PMCID: PMC174935.